Home > Oncology > BCC 2019 > St. Gallen Consensus > St. Gallen Consensus – Neoadjuvant Therapy and Residual Disease

St. Gallen Consensus – Neoadjuvant Therapy and Residual Disease

BCC 2019

Just as it was 2 years ago, almost all panellists (98.5%) endorsed neoadjuvant systemic treatment for patients with stage 2 or stage 3 triple-negative breast cancer, or with Her2-positive breast cancer. In addition, the panel this year voted about which type of neoadjuvant should be preferred in some specified subtypes of breast cancer. For example, in case of a postmenopausal patient with a luminal A subtype based on immunohistochemistry (or equivalent based on gene expression testing), 81% of the panellists preferred endocrine neoadjuvant therapy over neoadjuvant chemotherapy. This opinion means a clear shift in advantage of neoadjuvant endocrine therapy. Asked for their opinion on the appropriate duration of the endocrine neoadjuvant therapy in postmenopausal patients with a luminal A type tumour, 47% of the panellists preferred to continue endocrine neoadjuvant therapy until optimal reduction in tumour size is reached however long it takes, while 33% of the panellists preferr...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on